Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial

JAMA

Volumn 283, Issue 8, 2000, Pages 1007-1015

  Mulnard, Ruth A ^a   Cotman, Carl W ^a   Kawas, Claudia ^b   Van Dyck, Christopher H ^c   Sano, Mary ^d   Doody, Rachelle ^e   Koss, Elizabeth ^f   Pfeiffer, Eric ^g   Jin, Shelia ^h   Gamst, Anthony ^h   Grundman, Michael ^h   Thomas, Ronald ^h   Thal, Leon J ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c YALE UNIVERSITY   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MEMORY; MOOD; MOTOR PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034704547     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.8.1007     Document Type: Article

References (49)

1. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand. 1987;76:465-479.
2. Gould E, Woolly CS, Frankfurt M, McEwen BS. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci. 1990;10:1286-1291.
3. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol. 1985;89: 484-490.
4. Toran-Allerand CD, Miranda RC, Bentham WDL, et al. Estrogen receptors co-localize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA. 1990; 89:4668-4672.
5. Joseph JA, Kochman K, Roth GS. Reduction of motor behavioral deficits in senescence via chronic prolactin or estrogen administration: time course and putative mechanisms of action. Brain Res. 1989;550: 195-202.
6. McDermott JL, Kreutzberg JD, Liu B, Dluzen DE. Effects of estrogen treatment on sensorimotor task performance and brain dopamine concentrations in gonadectomized male and female CD-1 mice. Horm Behav. 1994;28:16-28.
7. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol. 1991; 78:991-995.
8. Sherwin B. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 1988;13:345-357.
9. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia - Alzheimer's type. Psychoneuroendocrinology. 1986;11:337-345.
10. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem. 1989;34:521-525.
11. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaio Y, Hagino N. Evaluation of estrogen in female patients with dementia of the Alzheimer type. Endocr J. 1994;41:361-371.
12. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology. 1999;24:657-677.
13. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
14. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of the patient for the clinician. J Psychiatr Res. 1975;12:189-198.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
16. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study: Clinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997;11:S22-S31.
17. Morris JC. The Clinical Dementia Rating Scale: current version and scoring rules. Neurology. 1993;43: 2412-2414.
18. Zuckerman M, Lubin B, Robins S. Validation of the Multiple Affect Adjective Checklist in clinical situations. J Consult Psychol. 1965;29:594.
19. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1994;141: 1356-1364.
20. Moss MB, Albert MS, Butters N, Payne M. Differential patterns of memory loss among patients with Alzheimer's disease, Huntington's disease, and alcoholic Korsakoff's syndrome. Arch Neurol. 1986;43: 239-246.
21. Mohs R, Knopman D, Petersen R, et al, for the Alzheimer's Disease Cooperative Study. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broadens its scope. Alzheimer Dis Assoc Disord. 1997;11:S13-S21.
22. Army Individual Test Battery: Manual of Directions and Scoring. Washington, DC: War Department Adjutant General's Office; 1944.
23. Wechsler D. Wechsler Adult Intelligence Scale - Revised. New York, NY: Psychological Corp; 1981.
24. Morris JC, Heyman A, Mohs RC, et al. The consortium to establish a registry for Alzheimer's disease (CERAD), I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39: 1159-1165.
25. Benton AL, Hamsher K. Multilingual Aphasia Examination Manual. Iowa City: University of Iowa; 1978.
26. Mathews CG, Klove W. Instruction Manual for the Adult Neuropsychological Test Battery. Madison: University of Wisconsin Medical Center; 1964.
27. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, Ariz: Neuropsychology Press; 1990.
28. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
29. Stern Y, Albert SM, Sano M, et al. Assessing patient dependence in Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 1994;49:M216-M222.
30. Frankfurt M, McKittrick CR, Mendelson SD, McEwen BS. Effect of 5,7-dihydroxytryptamine, ovariectomy and gonadal steroids on serotonin receptor binding in rat brain. Neuroendocrinology. 1994;59:245-250.
31. Kritzer MF, Kohama SC. Ovarian hormones differentially influence immunoreactivity for dopamine beta-hydroxylase, choline acetyltransferase, and serotonin in the dorsolateral prefrontal cortex of adult rhesus monkeys. J Comp Neurol. 1999;409:438-451.
32. Hidalgo A, Barami K, Iversen K, Goldman SA. Estrogens and non-estrogenic ovarian influences combine to promote the recruitment and decrease the turnover of new neurons in the adult female canary brain. J Neurobiol. 1995;27:470-487.
33. Pike CJ. Estrogen modulates neuronal bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease. J Neurochem. 1999; 72:1552-1563.
34. Dubal DB, Shughrue PJ, Wilson ME, Merchenthaler I, Wise PM. Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors. J Neurosci. 1999;19:6385-6393.
35. Toung TJ, Traystman RJ, Hum PD. Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke. 1998;29:1666-1670.
36. Simpkins JW, Green PS, Gridley KE, Singh M, de Fiebre NC, Rajakumar G. Role of estrogen replacement therapy and the prevention of neuronal loss associated with Alzheimer's disease. Am J Med. 1997; 103:19S-25S.
37. Paul SM, Purdy RH. Neuroactive steroids. FASEB J. 1992;6:2311-2322.
38. Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ER-alpha and ER-beta expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999;13:307-319.
39. Johnson JK, McCleary R, OshitaMH, Cotman CW. Initiation and propagation stages of beta-amyloid are associated with distinctive apolipoprotein E, age, and gender profiles. Brain Res. 1998;798:18-24.
40. Su JH, Satou T, Anderson AJ, Cotman CW. Upregulation of bcl-2 is associated with neuronal damage in Alzheimer's disease brain. Neuroreport. 1996; 7:437-440.
41. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology. 1996;45:1323-1328.
42. Dal Forno G, Rasmusson DX, Brandt JA, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol. 1996;53:345-350.
43. Craft S, Teri L, Edland SD, et al. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology. 1998;51:149-153.
44. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology. 1997;48:1517-1521.
45. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994;140:256-261.
46. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996;156:2213-2217.
47. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429-432.
48. Rodriguez MM, Grossberg GT. Estrogen as a psychotherapeutic agent. Clin Geriatr Med. 1998;14: 177-189.
49. Sloane PD. Advances in the treatment of Alzheimer's disease. Am Fam Physician. 1998;58:1577-1586.